A new analysis of hypertension guidelines suggests some older adults — mostly women — with slightly high blood pressure could safely hold off on medications if they’re in good health.
A new study published in the Journal American Medical Association showed that patients with an Cystatin C based estimated ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
The Phase III study FIND-CKD ( NCT05047263) — investigating the efficacy and safety of KERENDIA ® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic ...
First new drug in 30 years to slow kidney disease in type 1 diabetes ...
Barclays 28th Annual Global Healthcare Conference March 10, 2026 11:30 AM EDTCompany ParticipantsRyan Cohlhepp - ...
Diabetes is one of the leading causes of kidney disease worldwide, and India carries a particularly high burden of both conditions. What makes diabetic kidney disease especially concerning is that it ...